Venetoclax plus obinutuzumab - the first chemo... - CLL Support

CLL Support

23,250 members39,937 posts

Venetoclax plus obinutuzumab - the first chemotherapy-free, fixed-duration first line CLL treatment approved by Health Canada

AussieNeil profile image
AussieNeilPartnerAdministrator
10 Replies

* VENCLEXTA® (venetoclax) plus obinutuzumab is the first chemotherapy-free,

fixed-duration combination regimen approved by Health Canada for patients

with previously untreated chronic lymphocytic leukemia (CLL).

* Approval is based on data from the Phase 3 CLL14 trial, which showed that

patients treated with obinutuzumab plus one year of treatment with

VENCLEXTA had clinically meaningful and statistically significant

progression-free survival (PFS) and higher rates of undetectable minimal

residual disease compared to patients receiving a standard of care

chemoimmunotherapy regimen of obinutuzumab and chlorambucil

bloomberg.com/press-release...

This is an unlocked post: healthunlocked.com/cllsuppo...

Neil

Written by
AussieNeil profile image
AussieNeil
Partner
To view profiles and participate in discussions please or .
Read more about...
10 Replies
seelel profile image
seelel

If it's good for Canada, then here's hoping it will soon become good for Australia.

Canuck901 profile image
Canuck901

Excellent news! Thanks. Wonder which provinces have also approved this treatment

AussieNeil profile image
AussieNeilPartnerAdministrator in reply toCanuck901

It was my understanding that Health Canada manages the approval process for all of Canada, but the treatment funding is the responsibility of the respective provinces and territories. Is that correct?

Canuck901 profile image
Canuck901 in reply toAussieNeil

Yes that’s the just of if , so this should be available in 3-4 months . I also wonder if this would be available on compassionate basis by the AbbieVie.

Something for Canadians to discss with their CLL specialist.

I believe that this is the latest and probably most effective treatment for CLL at the moment.

I guess the only question is 12 months long enough ?

studebaker profile image
studebaker

Thank you Neil. This is excellent news. Unfortunately for me, I don’t qualify for the group of before untreated patients.

I am going to have discussion with my doctor about the possibility of adding Venetoclax after some time being on Acalabrutinib. Just the idea of being able to get longer time with no treatment is very appealing to me.

You must be getting there soon Neil. Good luck to you.

🤗

Dana

Canuck901 profile image
Canuck901 in reply tostudebaker

Yeah obinituzimab and Venetoclax looks like it’s just for first line treatment while the Rituximab and Venetoclax is for relapse

studebaker profile image
studebaker in reply toCanuck901

Good thing is there are possibilities for us. Since I already had Obinutuzumab as my first treatment, I have to discuss this with my doctor when the time comes if I would only have to take Venetoclax.

Where is our Spring ?

Dana

Canuck901 profile image
Canuck901 in reply tostudebaker

When did you get obinituzimab? Before your acalabrutnib?

studebaker profile image
studebaker in reply toCanuck901

Yes, my first treatment was Obinutuzumab and Chlorambucil. Acalabrutinib is my second run.

Canuck901 profile image
Canuck901 in reply tostudebaker

Since these combo therapies seem to become more prevalent now with Venetoclax. Woujd be a good Time to ask if Venetoclax can be added to acalabrutnib

Not what you're looking for?

You may also like...

Frontline Venetoclax/Obinutuzumab Approved in Europe for CLL

In some welcome good news, "The European Commission has approved a fixed-dose combination of...
AussieNeil profile image
Partner

Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL

Dated 1st September 2019 In a phase III trial of patients with previously untreated CLL...
Jm954 profile image
Administrator

AbbVie Pharm--positive phase 3 for CLL!

Hey, all, see this article about AbbVie pharma! AbbVie Sees Continued Positive Results for...
Vlaminck profile image

From the CLL14 Study: Venetoclax Plus Obinutuzumab Prolongs Progression Free Survival, Not Overall Survival , in CLL

These results, from the CLL14 study (ClinicalTrials.gov Identifier: NCT02242942), were presented at...
Jm954 profile image
Administrator

Health Canada approves Ibrutinib plus Rituximab for First Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Good News for our untreated Canadian members! This latest approval is based on...
AussieNeil profile image
Partner